美国FDA药品数据库-药物在线

商品名	申请号	产品号	申请类型	活性成分	剂型/给药途径	规格/剂量	RLD	RS	申请号原始批准/暂定批准日期	产品号批准日期	申请人	市场状态
EXELON	020823	003	NDA	RIVASTIGMINE TARTRATE	CAPSULE;ORAL	EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Yes	No	2000/04/21	2000/04/21	NOVARTIS	Discontinued
EXELON	020823	004	NDA	RIVASTIGMINE TARTRATE	CAPSULE;ORAL	EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Yes	No	2000/04/21	2000/04/21	NOVARTIS	Discontinued
EXELON	020823	005	NDA	RIVASTIGMINE TARTRATE	CAPSULE;ORAL	EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Yes	No	2000/04/21	2000/04/21	NOVARTIS	Discontinued
EXELON	020823	006	NDA	RIVASTIGMINE TARTRATE	CAPSULE;ORAL	EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Yes	No	2000/04/21	2000/04/21	NOVARTIS	Discontinued
EXELON	021025	001	NDA	RIVASTIGMINE TARTRATE	SOLUTION;ORAL	EQ 2MG BASE/ML	Yes	No	2000/04/21	2000/04/21	NOVARTIS	Discontinued
EXELON	022083	001	NDA	RIVASTIGMINE	FILM, EXTENDED RELEASE;TRANSDERMAL	4.6MG/24HR	Yes	No	2007/07/06	2007/07/06	SANDOZ	Prescription
EXELON	022083	002	NDA	RIVASTIGMINE	FILM, EXTENDED RELEASE;TRANSDERMAL	9.5MG/24HR	Yes	Yes	2007/07/06	2007/07/06	SANDOZ	Prescription
EXELON	022083	005	NDA	RIVASTIGMINE	FILM, EXTENDED RELEASE;TRANSDERMAL	13.3MG/24HR	Yes	No	2007/07/06	2012/08/31	SANDOZ	Prescription